Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

Stem cell therapy is emerging as a potential treatment for different conditions in endocrinology, including diabetes and ...

Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 ...

Charles River expanded the Memphis facility in November 2022, adding nine processing suites to its 16 clean rooms at the site ...

The U.S. FDA has granted Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease, and Orphan Drug designation, ...

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the ...

Imugene's trial programs could result in the first 'off the shelf' Car-T therapy that uses healthy donors' cells.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

A retrospective analysis showed improved overall survival (OS) with Orca-T compared with post-transplant cyclophosphamide in ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...